Coronaviridae Infections - Pipeline Review, H2 2016

  • ID: 3846525
  • Report
  • 101 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • AstraZeneca Plc
  • GeneCure LLC
  • Humabs BioMed SA
  • Nanotherapeutics, Inc.
  • Novavax, Inc.
  • Phelix Therapeutics, LLC
  • MORE
Coronaviridae Infections - Pipeline Review, H2 2016

Summary

‘Coronaviridae Infections - Pipeline Review, H2 2016’, provides an overview of the Coronaviridae Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Coronaviridae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Coronaviridae Infections and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Coronaviridae Infections
- The report reviews pipeline therapeutics for Coronaviridae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Coronaviridae Infections therapeutics and enlists all their major and minor projects
- The report assesses Coronaviridae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Coronaviridae Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Coronaviridae Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Coronaviridae Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AstraZeneca Plc
  • GeneCure LLC
  • Humabs BioMed SA
  • Nanotherapeutics, Inc.
  • Novavax, Inc.
  • Phelix Therapeutics, LLC
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Coronaviridae Infections Overview

Therapeutics Development

Pipeline Products for Coronaviridae Infections - Overview

Pipeline Products for Coronaviridae Infections - Comparative Analysis

Coronaviridae Infections - Therapeutics under Development by Companies

Coronaviridae Infections - Therapeutics under Investigation by Universities/Institutes

Coronaviridae Infections - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Coronaviridae Infections - Products under Development by Companies

Coronaviridae Infections - Products under Investigation by Universities/Institutes

Coronaviridae Infections - Companies Involved in Therapeutics Development

AstraZeneca Plc

CEL-SCI Corporation

GeneCure LLC

Gilead Sciences, Inc.

Hemispherx Biopharma, Inc.

Humabs BioMed SA

Inovio Pharmaceuticals, Inc.

Kineta, Inc.

Nanotherapeutics, Inc.

NanoViricides, Inc.

Novavax, Inc.

Organic Vaccines

Phelix Therapeutics, LLC

Planet Biotechnology Inc.

Protein Sciences Corporation

Regeneron Pharmaceuticals Inc

Coronaviridae Infections - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

CEL-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-3252 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FBR-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FDX-000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Severe Acute Respiratory Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-5734 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-4500 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon alfa-n3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon beta-1a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KIN-1400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LCA-60 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Middle East respiratory syndrome coronavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Middle East respiratory syndrome coronavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Middle East respiratory syndrome coronavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Middle East respiratory syndrome vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Middle East respiratory syndrome vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ML-188 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Coronavirus Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for SARS Virus Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBD-219N1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-3048 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-3051 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAB-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SARS (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

severe acute respiratory syndrome vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Middle East Respiratory Syndrome Human Coronavirus Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit 3CLpro for Coronavirus Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SSYA-10001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coronaviridae Infections - Dormant Projects

Coronaviridae Infections - Discontinued Products

Coronaviridae Infections - Product Development Milestones

Featured News & Press Releases

Aug 11, 2016: Phase I Clinical Trials Underway for First MERS Treatment

Aug 08, 2016: GeneOne Life Science Announces Full Enrollment of First-In-Human Study of MERS Vaccine

Jan 20, 2016: Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection as a Treatment of Middle East Respiratory Syndrome

Nov 19, 2015: GeneOne Life Science and Inovio Pharmaceuticals’ MERS Vaccine Approved for First-in-Human Study

Oct 19, 2015: Inovio and Partner Advance MERS Vaccine

Oct 19, 2015: Hemispherx Biopharma Europe Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients with Middle East Respiratory Syndrome

Jul 28, 2015: PNAS Paper Details Efficacy Of A Potent, Fully Human Antibody For The Treatment Of MERS

Jul 15, 2015: Hemispherx Biopharma Europe Submits Application for Orphan Medicine Designation to the EMA for Alferon N Injection for Treatment of Middle East Respiratory Syndrome

Jun 22, 2015: MERS coronavirus: Candidate vaccine gears up for clinical trials

Jun 04, 2015: Kineta’s Novel Broad Spectrum Antivirals Trigger Effective Natural Immune Response to Flu and Respiratory Virus Infections

Jun 16, 2014: Hemispherx Announces New Publication With Potential Insight Into High Mortality Rate in Middle Eastern Respiratory Syndrome (MERS)

Apr 30, 2014: New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus

Jun 06, 2013: Novavax Produces New Vaccine Candidate To Fight MERS-CoV Infection

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Coronaviridae Infections, H2 2016

Number of Products under Development for Coronaviridae Infections - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2016

Coronaviridae Infections - Pipeline by AstraZeneca Plc, H2 2016

Coronaviridae Infections - Pipeline by CEL-SCI Corporation, H2 2016

Coronaviridae Infections - Pipeline by GeneCure LLC, H2 2016

Coronaviridae Infections - Pipeline by Gilead Sciences, Inc., H2 2016

Coronaviridae Infections - Pipeline by Hemispherx Biopharma, Inc., H2 2016

Coronaviridae Infections - Pipeline by Humabs BioMed SA, H2 2016

Coronaviridae Infections - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016

Coronaviridae Infections - Pipeline by Kineta, Inc., H2 2016

Coronaviridae Infections - Pipeline by Nanotherapeutics, Inc., H2 2016

Coronaviridae Infections - Pipeline by NanoViricides, Inc., H2 2016

Coronaviridae Infections - Pipeline by Novavax, Inc., H2 2016

Coronaviridae Infections - Pipeline by Organic Vaccines, H2 2016

Coronaviridae Infections - Pipeline by Phelix Therapeutics, LLC, H2 2016

Coronaviridae Infections - Pipeline by Planet Biotechnology Inc., H2 2016

Coronaviridae Infections - Pipeline by Protein Sciences Corporation, H2 2016

Coronaviridae Infections - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Coronaviridae Infections - Dormant Projects, H2 2016

Coronaviridae Infections - Dormant Projects (Contd..1), H2 2016

Coronaviridae Infections - Dormant Projects (Contd..2), H2 2016

Coronaviridae Infections - Discontinued Products, H2 2016 90List of Figures

Number of Products under Development for Coronaviridae Infections, H2 2016

Number of Products under Development for Coronaviridae Infections - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AstraZeneca Plc
  • GeneCure LLC
  • Humabs BioMed SA
  • Nanotherapeutics, Inc.
  • Novavax, Inc.
  • Phelix Therapeutics, LLC
  • MORE
Coronaviridae Infections Coronaviruses are common viruses that most people get some time in their life. Human coronaviruses usually cause mild to moderate upper-respiratory tract illnesses. Coronaviruses spread from an infected person to others through air by coughing and sneezing, and close personal contact, such as touching or shaking hands. Coronavirus symptoms include rhinorrhea, sneezing, cough, nasal obstruction and bronchitis. Treatment includes antiviral medications and pain relievers.

Coronaviridae Infections pipeline therapeutics constitutes close to 31 molecules. Out of which approximately 24 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 13, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively.

Our latest report Coronaviridae Infections – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Coronaviridae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Coronaviridae Infections and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
AstraZeneca Plc
CEL-SCI Corporation
GeneCure LLC
Gilead Sciences, Inc.
Hemispherx Biopharma, Inc.
Humabs BioMed SA
Inovio Pharmaceuticals, Inc.
Kineta, Inc.
Nanotherapeutics, Inc.
NanoViricides, Inc.
Novavax, Inc.
Organic Vaccines
Phelix Therapeutics, LLC
Planet Biotechnology Inc.
Protein Sciences Corporation
Regeneron Pharmaceuticals Inc
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll